[
 {
  "id": 1,
  "abbreviation": "CO",
  "color": "#00a9e0",
  "created_at": null,
  "updated_at": null,
  "states_id": 6,
  "status": "Approved ",
  "wavier_status": "SPA ",
  "state_name": "Colorado",
  "": "",
  "faqs": [
    {
      "id": 1,
      "newtablestates_id": 1,
      "states_id": 6,
      "waiver_other": "<span style=\"font-weight:600; font-size:17px;\">SPA</span>",
      "status": "<span style=\"font-weight:600; font-size:17px;\">Approved</span>",
      "manufacturer": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
      "drug": "<span style=\"font-weight:600; font-size:17px;\">Physician-administered drugs</span>",
      "therapeuticarea": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
      "description": "State approved to negotiate supplemental rebate agreements involving value-based contracts with pharmaceutical companies. Value-based contracts would produce additional rebates that lower net cost for the state for drugs covered under such contracts, if clinical outcome targets for those drugs are not achieved. Colorado has not yet identified specific drugs or manufacturers it plans to approach with value-based contracts.",
      "year_implementation": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
      "duration_contact": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
      "tbd": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
      "new_type": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
      "source": "<a href=\"https://www.medicaid.gov/State-resource-center/Medicaid-State-Plan-Amendments/Downloads/CO/CO-18-0044.pdf\">https://www.medicaid.gov/State-resource-center/Medicaid-State-Plan-Amendments/Downloads/CO/CO-18-0044.pdf</a>",
      "created_at": "2019-04-16 11:29:29",
      "updated_at": "2019-04-16 08:11:23",
      "states": {
        "id": 6,
        "name": "Colorado",
        "abbreviation": "CO",
        "active": "1",
        "created_at": "2018-08-09 11:15:59",
        "updated_at": null
      }
    }
  ],
  "states": {
    "id": 6,
    "name": "Colorado",
    "abbreviation": "CO",
    "active": "1",
    "created_at": "2018-08-09 11:15:59",
    "updated_at": null
  }
},
  {
    "id": 2,
    "states_id": 18,
    "status": "Solicitation For Offers (SFO) Released sd",
    "wavier_status": "SFO",
    "created_at": null,
    "updated_at": null,
    "state_name": "Louisiana",
    "abbreviation": "LA",
	"color":"#f0ab00",
    "faqs": [
      {
        "id": 2,
        "newtablestates_id": 2,
        "states_id": 18,
        "waiver_other": "<span style=\"font-weight:600; font-size:17px;\">SFO</span>",
        "status": "<span style=\"font-weight:600; font-size:17px;\">Solicitation For Offers (SFO) Released</span>",
        "manufacturer": "<span style=\"font-weight:600; font-size:17px;\">Gilead,</span><span style=\"font-weight:600; font-size:17px;\">Merck,</span> and <span style=\"font-weight:600; font-size:17px;\">AbbVies</span> have expressed interest in participating",
        "drug": "<span style=\"font-weight:600; font-size:17px;\">Hepatitis C drugs</span>",
        "therapeuticarea": "<span style=\"font-weight:600; font-size:17px;\">Infectious Diseas</span>",
        "description": "<p>The state is seeking drug makers willing to supply treatments in return for a capped payment amount. The state would agree to pay for unlimited access to medication for anyone who is enrolled in the state Medicaid program or incarcerated in a state prison, up to a capped amount.</p>\r\n\r\n<p>A manufacturer that signs an agreement will provide rebates to the state Medicaid program and, for incarcerated patients, the manufacturer will use the federal 340B drug pricing program, which requires drug makers to offer discounts of up to 50 percent on all outpatient drugs to hospitals and clinics that are known as safety-net hospitals because they serve indigent populations.</p>\r\n\r\n<p>The model will be operated through the state's Medicaid and incarceration programs.</p>",
        "year_implementation": "<span style=\"font-weight:600; font-size:17px;\">2019</span>",
        "duration_contact": "<span style=\"font-weight:600; font-size:17px;\">7/1/19 - 6/2024</span>",
        "tbd": "<span style=\"font-weight:600; font-size:17px;\">2019</span>",
        "new_type": "Capped Contract",
        "source": "<a href=\"http://ldh.la.gov/index.cfm/newsroom/detail/5020\" target=\"_blank\">http://ldh.la.gov/index.cfm/newsroom/detail/5020</a>",
        "created_at": "2019-04-16 00:00:00",
        "updated_at": "2019-04-16 00:00:00",
        "states": {
          "id": 18,
          "name": "Louisiana",
          "abbreviation": "LA",
          "active": "1",
          "created_at": "2018-08-09 11:18:23",
          "updated_at": null
        }
      }
    ],
    "states": {
      "id": 18,
      "name": "Louisiana",
      "abbreviation": "LA",
      "active": "1",
      "created_at": "2018-08-09 11:18:23",
      "updated_at": null
    }
  },
  {
    "id": 3,
    "states_id": 22,
    "status": "Approved ",
    "wavier_status": "SPA ",
    "created_at": null,
    "updated_at": null,
    "state_name": "Michigan",
    "abbreviation": "MI",
    "color":"#00a9e0",
    "faqs": [
      {
        "id": 3,
        "newtablestates_id": 3,
        "states_id": 22,
        "waiver_other": "<span style=\"font-weight:600; font-size:17px;\">SPA</span>",
        "status": "<span style=\"font-weight:600; font-size:17px;\">Approved</span> ",
        "manufacturer": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
        "drug": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
        "therapeuticarea": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
        "description": "Michigan received CMS approval of its plan to enter into outcomes-based contracts under its Medicaid program on November 14, 2018 ",
        "year_implementation": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
        "duration_contact": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
        "tbd": "<span style=\"font-weight:600; font-size:17px;\">TBD</span>",
        "new_type": "<span style=\"font-weight:600; font-size:17px;\">OBC</span>",
        "source": "",
        "created_at": "2019-04-12 10:15:28",
        "updated_at": "2019-04-16 08:11:23",
        "states": {
          "id": 22,
          "name": "Michigan",
          "abbreviation": "MI",
          "active": "1",
          "created_at": "2018-08-09 11:19:10",
          "updated_at": null
        }
      }
    ],
    "states": {
      "id": 22,
      "name": "Michigan",
      "abbreviation": "MI",
      "active": "1",
      "created_at": "2018-08-09 11:19:10",
      "updated_at": null
    }
  },
  {
    "id": 4,
    "states_id": 36,
    "status": "Approved ",
    "wavier_status": "SPA ",
    "created_at": null,
    "updated_at": null,
    "state_name": "Oklahoma",
    "abbreviation": "OK",
	"color":"#004157",
    "faqs": [
      {
        "id": 4,
        "newtablestates_id": 4,
        "states_id": 36,
        "waiver_other": "<span style=\"font-weight:600; font-size:17px;\">SPA </span>",
        "status": "<span style=\"font-weight:600; font-size:17px;\">Approved </span>",
        "manufacturer": "<span style=\"font-weight:600; font-size:17px;\">Melinta Therapeutics</span>",
        "drug": "<span style=\"font-weight:600; font-size:17px;\">Orbactiv (oritavancin)</span>",
        "therapeuticarea": "<span style=\"font-weight:600; font-size:17px;\">Antibiotic</span>",
        "description": "Under the new value-based contract, prior authorization will no longer be required. In return for having the drug listed as a first-line treatment, Melinta ensures that oritavancin will not result in a net increase in costs. However, under the terms of the value-based contract, if the state does incur higher costs from oritavancin – despite the avoided hospitalizations — Melinta will be required to cover those costs through additional rebates to the state.",
        "year_implementation": "<span style=\"font-weight:600; font-size:17px;\">2018</span>",
        "duration_contact": "<span style=\"font-weight:600; font-size:17px;\">N/A</span>",
        "tbd": "<span style=\"font-weight:600; font-size:17px;\">2018</span>",
        "new_type": "OBC",
        "source": "<a href=\"https://www.healthcare-economist.com/2018/09/30/oklahomas-medicaid-program-experiments-with-outcomes-based-contracts/\" target=\"_blank\">https://www.healthcare-economist.com/2018/09/30/oklahomas-medicaid-program</a>",
        "created_at": "2019-04-16 00:00:00",
        "updated_at": "2019-04-16 00:00:00",
        "states": {
          "id": 36,
          "name": "Oklahoma",
          "abbreviation": "OK",
          "active": "1",
          "created_at": "2018-08-09 11:22:10",
          "updated_at": null
        }
      },
      {
        "id": 5,
        "newtablestates_id": 4,
        "states_id": 36,
        "waiver_other": "<span style=\"font-weight:600; font-size:17px;\">SPA </span>",
		"color":"#004157",
        "status": "<span style=\"font-weight:600; font-size:17px;\">Approved</span>",
        "manufacturer": "<span style=\"font-weight:600; font-size:17px;\">Alkermes Plc</span>",
        "drug": "<span style=\"font-weight:600; font-size:17px;\">Aristada (aripiprazole lauroxil)</span>",
        "therapeuticarea": "<span style=\"font-weight:600; font-size:17px;\">Mental Health</span>",
        "description": "Allows the state of Oklahoma to negotiate supplemental rebate agreements involving value-based purchasing arrangements with drug manufacturers that could produce extra rebates for the state if clinical outcomes are not achieved. Contract ties rebates for schizophrenia drug to patient adherence. List prices for the long-acting drug, given every month to six weeks, start at about $1,200 a month. Under the one-year contract, the price decreases every other month as long as the prescription is refilled.",
        "year_implementation":"<span style=\"font-weight:600; font-size:17px;\"> 2018</span>",
        "duration_contact": "<span style=\"font-weight:600; font-size:17px;\">N/A</span>",
        "tbd": "<span style=\"font-weight:600; font-size:17px;\">2018</span>",
        "new_type": "OBC",
        "source": "<a href=\"https://www.reuters.com/article/us-health-usa-medicaid/oklahoma-medicaid-tests-new-tactic-to-curb-u-s-drug-costs-idUSKCN1L81L6\">https://www.reuters.com/article/us-health-usa-medicaid/oklahoma-medicaid-tests-new-tactic-to-curb-u-s-drug-costs-idUSKCN1L81L6</a>",
        "created_at": "2019-04-16 00:00:00",
        "updated_at": "2019-04-16 00:00:00",
        "states": {
          "id": 36,
          "name": "Oklahoma",
          "abbreviation": "OK",
          "active": "1",
          "created_at": "2018-08-09 11:22:10",
          "updated_at": null
        }
      },
      {
        "id": 6,
        "newtablestates_id": 4,
        "states_id": 36,
        "waiver_other": "<span style=\"font-weight:600; font-size:17px;\">SPA</span>",
		"color":"#004157",
        "status": "<span style=\"font-weight:600; font-size:17px;\">Approved</span>",
        "manufacturer": "<span style=\"font-weight:600; font-size:17px;\">Eisai Inc.</span>",
        "drug": "<span style=\"font-weight:600; font-size:17px;\">FYCOMPA (perampanel)</span>",
        "therapeuticarea": "<span style=\"font-weight:600; font-size:17px;\">Neurological</span>",
        "description": "Eisai Inc. the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that they have signed a value-based contract for FYCOMPA® (perampanel) CIII with Oklahoma Health Care Authority (OHCA) premised on reduction of hospitalizations of OHCA patients with epilepsy.",
        "year_implementation": "<span style=\"font-weight:600; font-size:17px;\">2018</span>",
        "duration_contact": "<span style=\"font-weight:600; font-size:17px;\">N/A</span>",
        "tbd": "<span style=\"font-weight:600; font-size:17px;\">2018</span>",
        "new_type": "OBC",
        "source": "<a href=\"http://eisai.mediaroom.com/2018-10-24-Eisai-and-Oklahoma-Health-Care-Authority-Enter-Value-Based-Agreement-for-FYCOMPA\" target=\"_blank\">http://eisai.mediaroom.com/2018-10-24</a>",
        "created_at": null,
        "updated_at": null,
        "states": {
          "id": 36,
          "name": "Oklahoma",
          "abbreviation": "OK",
          "active": "1",
          "created_at": "2018-08-09 11:22:10",
          "updated_at": null
        }
      },
      {
        "id": 7,
        "newtablestates_id": 4,
        "states_id": 36,
        "waiver_other": "<span style=\"font-weight:600; font-size:17px;\">SPA </span>",
		"color":"#004157",
        "status": "<span style=\"font-weight:600; font-size:17px;\">Approved</span>",
        "manufacturer": "<span style=\"font-weight:600; font-size:17px;\">Janssen Pharmaceuticals </span>",
        "drug": "<span style=\"font-weight:600; font-size:17px;\">INVEGA SUSTENNA (paliperidone palmitate) \r\nINVEGA TRINZA (paliperidone palmitate)</span>",
        "therapeuticarea": "<span style=\"font-weight:600; font-size:17px;\">Mental Health</span>",
        "description": "Under this arrangement focused on enabling the use of INVEGA SUSTENNA® (paliperidone palmitate) and INVEGA TRINZA® (paliperidone palmitate) earlier in treatment of adults with schizophrenia, OHCA aims to improve care among patients with schizophrenia and reduce expenses for medical services. ",
        "year_implementation": "<span style=\"font-weight:600; font-size:17px;\">2018</span>",
        "duration_contact": "<span style=\"font-weight:600; font-size:17px;\">N/A</span>",
        "tbd": "<span style=\"font-weight:600; font-size:17px;\">2018</span>",
        "new_type": "<span style=\"font-weight:600; font-size:17px;\">OBC</span>",
        "source": "<a href=\"https://www.prnewswire.com/news-releases/janssen-signs-results-based-contract-with-oklahoma-health-care-authority-ohca-for-its-long-acting-injectable-schizophrenia-medicines-300765003.html\" target=\"_blank\"> https://www.prnewswire.com/news-releases </a>",
        "created_at": null,
        "updated_at": null,
        "states": {
          "id": 36,
          "name": "Oklahoma",
          "abbreviation": "OK",
          "active": "1",
          "created_at": "2018-08-09 11:22:10",
          "updated_at": null
        }
      }
    ],
    "states": {
      "id": 36,
      "name": "Oklahoma",
      "abbreviation": "OK",
      "active": "1",
      "created_at": "2018-08-09 11:22:10",
      "updated_at": null
    }
  },
  {
    "id": 5,
    "states_id": 47,
    "status": "RFP Released ",
    "wavier_status": "RFP",
    "created_at": null,
    "updated_at": null,
    "state_name": "Washington",
    "abbreviation": "WA",
	"color":"#e4a11b",
    "faqs": [
      {
        "id": 8,
        "newtablestates_id": 5,
        "states_id": 47,
        "waiver_other": "<span style=\"font-weight:600; font-size:17px;\">RFP</span>",
        "status": "<span style=\"font-weight:600; font-size:17px;\">RFP Released </span>",
        "manufacturer": "<span style=\"font-weight:600; font-size:17px;\">Gilead</span>, <span style=\"font-weight:600; font-size:17px;\">Merck</span>, and <span style=\"font-weight:600; font-size:17px;\">AbbVie</span> submitted questions about the proposal",
        "drug": "<span style=\"font-weight:600; font-size:17px;\">Hepatitis C drugs</span>",
        "therapeuticarea": "<span style=\"font-weight:600; font-size:17px;\">Infectious Disease</span>",
        "description": "State is proposing a modified subscription model for Medicaid that would guarantee a net unit price after meeting a specified annual spending level, and a guaranteed net unit price for non-Medicaid payer. The state is also requiring bidders to provide bona fide services -- supplemental healthcare services beyond provision HCV medicine. ",
        "year_implementation":"<span style=\"font-weight:600; font-size:17px;\"> 2019</span>",
        "duration_contact": "<span style=\"font-weight:600; font-size:17px;\">7/1/19 – 6/30/23</span> with option for 2 year extension",
        "tbd": "<span style=\"font-weight:600; font-size:17px;\">2019</span>",
        "new_type": "Winner Takes All ",
        "source": "<a href=\"https://www.statnews.com/pharmalot/2019/02/06/washington-netflix-hepatitis-drug-prices/\" target=\"_blank\">https://www.statnews.com/pharmalot/2019</a>",
        "created_at": null,
        "updated_at": null,
        "states": {
          "id": 47,
          "name": "Washington",
          "abbreviation": "WA",
          "active": "1",
          "created_at": "2018-08-09 11:26:22",
          "updated_at": null
        }
      }
    ],
    "states": {
      "id": 47,
      "name": "Washington",
      "abbreviation": "WA",
      "active": "1",
      "created_at": "2018-08-09 11:26:22",
      "updated_at": null
    }
  }
]